Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

BMS Expands Dealings With Otsuka

by Alexander H. Tullo
April 13, 2009 | A version of this story appeared in Volume 87, Issue 15

Bristol-Myers Squibb and Japan's Otsuka Pharmaceutical have expanded an existing development and commercialization deal and set up a new one in oncology. The two companies have extended their deal for the antipsychosis drug Abilify by three years to 2015. They will also jointly develop and sell the BMS oncology products Sprycel and Ixempra. BMS will pay Otsuka $400 million in cash up front and a share of product sales, and Otsuka will contribute to commercialization expenses.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.